BioSpace News Archive

Drug Development

New Hope for ALS Patients Worldwide: Kadimastem Commences Its Clinical Trial in ALS Patients at Hadassah Medical Center After it Received Approval From the Ministry of Health

Kadimastem announced that it has received the approval of the Ministry of Health’s Supreme Committee, for conducting its phase I/IIa clinical trial in ALS patients using the unique cell therapy developed by the company.

March 13, 2018
·
4 min read
Biotech Beach

Escalier Biosciences Raises $19 Million to Develop its Topical and Systemic RORγt Therapies for Psoriasis and other Autoimmune Diseases

Escalier Biosciences BV announced the closing of a $19 million Series B financing.

March 13, 2018
·
1 min read
Drug Development

BiondVax Appoints CRO to Conduct Pivotal Clinical Efficacy Phase 3 Trial of Its Novel Universal Flu Vaccine Candidate

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the Universal Flu Vaccine candidate M-001, announced today the signing of a Master Service Agreement (MSA) with a contract research organization (CRO) to conduct the first pivotal, clinical efficacy, Phase 3 trial of M-001.

March 13, 2018
·
4 min read
Business

Boehringer Ingelheim and Vanderbilt University Expand Partnership to Develop Novel Treatment Approaches for Cancer

-- Boehringer Ingelheim and Vanderbilt University collaborate to develop novel anti-cancer drugs that inhibit the MCL1 (myeloid cell leukemia 1) protein -- There are no existing therapies targeting MCL1, which is highly prevalent in many difficult-to-treat cancers -- This is the third collaboration between Boehringer Ingelheim and Vanderbilt University

March 13, 2018
·
5 min read
Biotech Bay

Study adds to understanding about utility of ultra-sensitive cardiac troponin measurement in diagnosing and predicting cardiovascular syndromes

Cardiac troponin I (cTnI) concentrations measured with the Singulex ultrasensitive cTnI assay, powered by Single Molecule Counting technology, were associated with a higher prevalence of coronary artery disease (CAD) and independently predicted cardiovascular events in patients with obstructive and non-obstructive CAD, according to a study published in the Journal of the American Heart Association.

March 13, 2018
·
3 min read
PRN Therapeutics launches nūretin®

PRN Therapeutics, the world’s leading producer of condition-specific eye care products, today announced the launch of a novel medical food formulated to reduce the risk of and slow the progression to diabetic retinopathy.

March 13, 2018
·
2 min read
Business

Arrevus announces three new appointments to the company’s Board Of Directors

Arrevus Inc., a biotechnology company developing chaperone protein inhibitors to combat antimicrobial resistance, announced the addition of three new board members: Barry Garfinkle, Joe McMahon, and Joe St. Geme.

March 13, 2018
·
2 min read
Drug Development

Temple Therapeutics Announces Unprecedented Clinical Data for Novel Drug Evitar

Unprecedented Clinical Data Could Capture $3B Uncontested Market

March 13, 2018
·
2 min read
Business

PAREXEL and CHA Medical Group Partner to Enhance Early Phase Clinical Research in Korea

Collaboration combines best-in-class offerings from CHA and PAREXEL to enhance early phase clinical trials in growing hub for drug development

March 13, 2018
·
2 min read
Drug Development

Reflow Medical Announces Enrollment of Its First Patients in the Wing-IT IDE Clinical Trial

(A Non-Randomized Study Evaluating the Use of the Reflow Medical Wingman Catheter to Cross Chronic Total Occlusions in Infrainguinal Peripheral ArTeries)

March 13, 2018
·
1 min read